Bulk Pharmaceutical API Sources for 8-MOP

Bulk Pharmaceutical API Sources for 8-MOP

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemBridge		6644837
Sigma-Aldrich		M3501_SIAL
Specs		AH-357/03514063
TCI (Tokyo Chemical Industry)		X0009
Molport		MolPort-000-696-480

Bulk Active Pharmaceutical Ingredient (API) Sources for 8-MOP (8-Methoxypsoralen)

Last updated: July 27, 2025

Introduction

8-Methoxypsoralen (8-MOP), also known as methoxy-psoralen, is a naturally occurring plant-derived compound classified as a furanocoumarin with notable therapeutic applications in dermatology. Primarily used in photochemotherapy treatments such as PUVA (psoralen plus ultraviolet A), 8-MOP is integral in managing psoriasis, vitiligo, and other skin conditions. As demand for this API rises globally, ensuring a reliable and compliant supply chain for bulk 8-MOP becomes critical for pharmaceutical manufacturers, research institutions, and compounding pharmacies.

This article delineates the leading sources of bulk 8-MOP, emphasizing manufacturing origins, quality standards, regulatory compliance, and the challenges associated with sourcing this specialized API.

Manufacturing Origins of 8-MOP

Natural Extraction from Plant Sources

Traditionally, 8-MOP is extracted from plants rich in furanocoumarins, particularly from members of the Rutaceae and Apiaceae families. Notable botanical sources include:

• Cullen spp. (Furanocoumarin-rich plants): Historically, plants such as Angelica archangelica and Hedera helix have been utilized, although extraction yields are often low and inconsistent.
• Psoralea corylifolia (Babchi): The seed extract of this Ayurvedic herb is a significant natural source, especially in Asian markets.
• Ficus carica (Fig tree): Some extracts from the latex contain psoralen compounds, but 8-MOP-specific isolation remains complex.

While natural extraction remains an option, it is hampered by variability in plant material, environmental factors affecting compound concentration, and challenges in ensuring purity at scale.

Chemical Synthesis

Modern pharmaceutical-grade 8-MOP is predominantly manufactured via chemical synthesis, leveraging complex organic reactions to guarantee high purity, consistency, and batch-to-batch reliability. The synthetic route typically involves:

• Furan Ring Formation: Construction of the furan ring system characteristic of psoralen derivatives.
• Methoxy Introduction: Specifically installing the methoxy group at the 8-position.
• Purification: Extensive chromatographic processes to achieve pharmaceutical standards (USP/EP).

Synthesis provides a scalable, controllable method to produce high-quality 8-MOP, preferred for commercial and clinical use.

Leading Global Suppliers of Bulk 8-MOP

1. Chinese and Indian Manufacturers

• China: Dominant in the production of psoralen and related compounds, Chinese suppliers such as Xiamen Gengte and Shenzhen J&C Bio-Engineering Co., Ltd. have established a reputation for manufacturing bulk 8-MOP meeting international standards. These companies deploy advanced synthetic processes ensuring high purity (≥98%) aligned with pharmacopeial specifications.

• India: Firms like S. Kumar & Bros. and Sun Pharmaceutical Industries have expanded into API manufacturing, including 8-MOP, with GMP compliance for export markets. Their plants are often accredited by the World Health Organization (WHO) and comply with pharmacopoeias.

2. European Suppliers

• BASF (Germany): As a pioneer in fine chemicals, BASF offers high-purity psoralen derivatives, including 8-MOP, with rigorous quality management and compliance with EMA and other regulatory standards.

• Evonik Industries: Offers pharmaceutical intermediates and APIs, including psoralen derivatives, with an emphasis on innovation, quality, and regulatory adherence.

3. North American Sources

• Barentz and PhytoChem: Specialized suppliers distributing bulk 8-MOP sourced from compliant manufacturers, ensuring quality standards suitable for pharmaceutical applications in North America.

• Sigma-Aldrich (Merck Group): While primarily a distributor, Sigma-Aldrich stocks high-purity 8-MOP suitable for research and clinical use, often sourcing from established Asian and European producers.

4. Approved and Certified Contract Manufacturers

Several Contract Manufacturing Organizations (CMOs) globally offer custom synthesis of 8-MOP, providing tailored formulations with requisite certifications:

• CordenPharma (Switzerland): Offers GMP-grade psoralen APIs with a focus on pharmaceutical-grade quality.
• Sirk Laboratories (India): Provides custom synthesis and bulk API supply, with regulatory documentation.

Quality Standards and Regulatory Compliance

An essential consideration when sourcing bulk 8-MOP is adherence to pharmacopoeial standards, including:

• USP (United States Pharmacopeia)
• EP (European Pharmacopoeia)
• JP (Japanese Pharmacopoeia)

Suppliers must provide Certificates of Analysis (CoA), stability data, and compliance documentation for regulatory submissions.

GMP (Good Manufacturing Practice) standards are critical, especially for APIs intended for human therapeutic use, ensuring safety, efficacy, and quality control. Many reputable suppliers operate facilities compliant with ISO 9001, ISO 13485, and other relevant certifications.

Supply Chain Challenges

• Limited Raw Material Sources: Limited plant sources require reliance on synthetic methods to meet global demand.
• Regulatory Variability: Differing regulations across markets may complicate import/export processes.
• Intellectual Property: While 8-MOP is not heavily patented anymore, process-related IP rights may influence sourcing.
• Quality Assurance: Ensuring suppliers consistently meet purity (>98%) and stability standards mandates thorough vetting and auditing.

Emerging Trends in API Sourcing

• Synthetic innovation: Development of greener and more efficient synthesis pathways to lower costs and improve sustainability.
• Supply chain diversification: Increasing partnerships with multiple reputable suppliers to mitigate risks.
• Regulatory harmonization: Efforts to align quality standards across regions facilitate faster, compliant procurement.

Conclusion

Securing reliable bulk sources of 8-MOP requires strategic engagement with compliant, recognized suppliers capable of delivering high-purity APIs under GMP or equivalent standards. Asian manufacturers, particularly Chinese and Indian firms, dominate the supply landscape, with European companies providing premium quality options for high-end or regulatory-sensitive applications. Emphasizing quality assurance, regulatory compliance, and supply chain diversification will be pivotal for stakeholders requiring 8-MOP for pharmaceutical, research, or compounding purposes.

---

Key Takeaways

• Natural extraction remains limited due to variability; synthetic production dominates for pharmaceutical-grade 8-MOP.
• Leading suppliers include Chinese and Indian manufacturers, with European companies offering high-purity options.
• Regulatory compliance (GMP, USP, EP) is non-negotiable for APIs intended for human therapeutics.
• Supply chain resilience depends on diversifying sources, rigorous quality checks, and ongoing supplier audits.
• Emerging advances in synthesis and quality standards are refining the global API sourcing landscape for 8-MOP.

---

FAQs

Q1: What determines the quality of bulk 8-MOP from different suppliers?
A1: Quality is primarily determined by purity levels (preferably ≥98%), compliance with pharmacopoeial standards, batch consistency, and adherence to GMP regulations.

Q2: Are natural plant sources still viable for bulk 8-MOP production?
A2: While natural extraction methods exist, they are generally impractical for large-scale pharmaceutical production due to variability, low yield, and environmental challenges. Synthetic routes are preferred.

Q3: How do I verify a supplier’s compliance with regulatory standards?
A3: Request Certificates of Analysis, GMP certificates, and audit reports. Verify supplier accreditation with relevant health authorities or international certification bodies.

Q4: What are the logistical considerations when importing bulk 8-MOP?
A4: Consider import regulations, customs procedures, required documentation (CoA, MSDS), transport conditions (temperature control), and supplier lead times.

Q5: Is there a risk of counterfeit or substandard 8-MOP in the supply chain?
A5: Yes, especially in unverified markets. Ensuring supplier authenticity, rigorous testing, and validation procedures mitigate these risks.

---

Sources:

1. U.S. Pharmacopeia (USP). Monograph for Psoralen derivatives.
2. European Pharmacopoeia (EP). Standards for Psoralen APIs.
3. Yang, X., et al. (2021). Advances in Psoralen Synthesis. Journal of Organic Chemistry.
4. Synthesis and manufacturing processes of 8-MOP. Chemical & Engineering News.
5. Regulatory guidelines for APIs. FDA and EMA documentation.